Bcr-Abl inhibition as a modality of CML therapeutics.
Buchdunger
E
E
Novartis Pharma AG, Research Oncology, Basel, Switzerland.
Matter
A
A
Druker
B J
BJ
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001665:Binding Sites; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D008958:Models, Molecular; D010879:Piperazines / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D016898:Interferon-alpha; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea